Latest Regulatory Framework News

Arovella Therapeutics has secured a crucial regulatory nod from the U.S. FDA, allowing its lead CAR-iNKT cell therapy, ALA-101, to enter first-in-human clinical trials targeting blood cancers.

Torque Metals is advancing its Paris Gold Camp project in Western Australia, moving from exploration to development readiness with a 250,000-ounce gold resource and an aggressive drilling program.

Key Petroleum Limited progresses its Potential Commercial Area applications in Queensland’s Cooper-Eromanga Basin, anticipating government approval by year-end, while planning a capital raise to bolster its limited cash reserves.

Gold Mountain Limited has reported promising assay results from its Irajuba Prospect in Brazil, revealing significant extensions to rare earth mineralisation and setting the stage for expanded resource drilling.

The ACCC has referred Ampol’s acquisition of EG Australia to a detailed Phase 2 review, citing concerns that the deal could significantly reduce competition in key Australian fuel markets.

Firebrick Pharma has introduced its Nasodine Throat Spray in Singapore, marking its first international product launch and setting the stage for further global rollouts in 2026.

Viking Mines reports promising high-grade tungsten oxide assay results from its Linka Tungsten Project in Nevada, reinforcing the project's potential amid soaring global scheelite prices.

The Calmer Co. International Limited has reported its highest ever monthly sales of $910,767 in December 2025, driven by strong wholesale growth and expanding US market presence.

Midas Minerals has reported a significant new high-grade copper and silver find at its Spaatzu Prospect within Namibia’s Otavi Copper Project, marking a promising expansion near the established T-13 deposit.

Energy Transition Minerals (ETM) has appointed Ballard Partners as strategic advisors in the US, reinforcing its plan to list on the Nasdaq Stock Exchange and deepen its engagement with American stakeholders.

Rio Tinto and Glencore have entered preliminary talks about a possible all-share merger via a Court-sanctioned scheme of arrangement, though no firm offer has been made. The mining giants have until early February to decide on progressing the deal.

Nyrada has secured ethics approval to begin a pivotal Phase IIa trial of its drug Xolatryp, targeting heart attack damage. Patient dosing is set to start in March 2026 across multiple Australian hospitals.